Fujian Aonong Biological Technology Group Incorporation Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

You Lin Wu

Chief executive officer

CN¥699.9k

Total compensation

CEO salary percentage	n/a
CEO tenure	8.8yrs
CEO ownership	10.3%
Management average tenure	4.6yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

Market Cool On Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Revenues Pushing Shares 30% Lower

May 02

CEO

You Lin Wu (46 yo)

8.8yrs

Tenure

CN¥699,900

Compensation

Mr. You Lin Wu serves as the Chairman of the Board of Directors and General Manager at Fujian Aonong Biological Technology Group Incorporation Limited and has been its Director since August 27, 2015. Mr. W...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
You Lin Wu	Chairman of the Board of Directors & GM	no data	CN¥699.90k	10.31% CN¥ 393.9m
Huadong Huang	Vice Chairman of the Board	8.8yrs	CN¥746.60k	0.22% CN¥ 8.3m
Ze Sen Huang	Deputy GM & Financial Director	5.7yrs	CN¥629.40k	0.048% CN¥ 1.8m
Haofeng Hou	Deputy GM & Secretary to the Board of Directors	8.8yrs	CN¥761.00k	0.20% CN¥ 7.8m
Hai Feng Li	Deputy General Manager	5.7yrs	CN¥625.00k	0.10% CN¥ 3.9m
Sihu Guo	Deputy General Manager	4.6yrs	CN¥656.80k	0.035% CN¥ 1.3m
Jun Lai	Deputy General Manager	4.6yrs	CN¥705.00k	0.040% CN¥ 1.5m
Jingquan Yang	Deputy General Manager	2.7yrs	CN¥616.30k	0.016% CN¥ 627.7k
Yuanxiang Hong	Deputy General Manager	2.7yrs	CN¥749.50k	0.034% CN¥ 1.3m
Zuoming Luo	Deputy General Manager	2.7yrs	CN¥616.00k	0.012% CN¥ 461.5k
Jianping Yang	Accounting Supervisor	no data	no data	no data

4.6yrs

Average Tenure

46yo

Average Age

Experienced Management: 603363's management team is considered experienced (4.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
You Lin Wu	Chairman of the Board of Directors & GM	8.8yrs	CN¥699.90k	10.31% CN¥ 393.9m
Huadong Huang	Vice Chairman of the Board	8.8yrs	CN¥746.60k	0.22% CN¥ 8.3m
Feng Liu	Independent Director	2.7yrs	CN¥120.00k	0.0033% CN¥ 125.7k
Jing Xue Zhang	Supervisor	8.8yrs	no data	0.27% CN¥ 10.5m
Zu Yao Huang	Vice Chairman	8.8yrs	CN¥374.10k	0.70% CN¥ 26.9m
Qing Qi Wen	Chairman of the Supervisory Board	8.8yrs	no data	0.28% CN¥ 10.9m
Junbiao Ye	Director	2.7yrs	CN¥745.90k	0.24% CN¥ 9.0m
Nengshui Ding	Director	5.7yrs	CN¥1.01m	0.042% CN¥ 1.6m
Junfeng Xiao	Employee Representative Supervisor	2.7yrs	no data	no data
Jun Wu	Director	4.5yrs	CN¥783.00k	0.11% CN¥ 4.2m
Luying Zheng	Independent Director	2.7yrs	CN¥120.00k	no data
Chunxiang Ai	Independent Director	2.7yrs	CN¥120.00k	no data

5.1yrs

Average Tenure

49yo

Average Age

Experienced Board: 603363's board of directors are considered experienced (5.1 years average tenure).

Fujian Aonong Biological Technology Group Incorporation Management

Management criteria checks 4/4

Key information

Recent management updates

Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 06, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 06, 2024

Market Cool On Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Revenues Pushing Shares 30% Lower

Less than half of directors are independent

Fujian Aonong Biological Technology Group Incorporation Limited to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Share price stability

Fujian Aonong Biological Technology Group Incorporation Limited to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: CN¥0.56 loss per share (vs CN¥0.12 profit in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.71 loss per share (vs CN¥0.42 loss in 2Q 2022)

First quarter 2023 earnings released: CN¥0.21 loss per share (vs CN¥0.54 loss in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.50 loss in 3Q 2021)

Now 20% undervalued after recent price drop

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.50 loss per share (vs CN¥0.25 profit in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.54 loss per share (vs CN¥0.33 profit in 2Q 2020)

Price target increased to CN¥29.16

First quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.27 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.95 (vs CN¥0.054 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: CN¥15.51

Investor sentiment improved over the past week

New 90-day low: CN¥12.37

New 90-day low: CN¥13.15

New 90-day low: CN¥13.54

Fujian Aonong Biological Technology Group Incorporation Limited to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥13.63

Liu Xueke, Su Guoyang, Wu Boyuan, and Liu Lianlong agreed to acquire 21% stake in Xiamen Aomu Trade Co., Ltd from Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) for CNY 0.

New 90-day low - CN¥20.10

Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) completed the acquisition of the remaining 70% stake in Xiamen Yinxiang Meat Industry Co., Ltd. from Xiamen Yinxiang Group Co., Ltd.

New 90-day high - CN¥26.31

Earnings released

Fujian Aonong Biological Technology Group Incorporation Limited to Report First Half, 2020 Results on Aug 20, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age